Alzheimer's Index
5348 views
Rate Now: 1 2 3 4

average rating: 3.50 / 2 ratings
Created by Barrons
DESCRIPTION:

Date updated:03-31-2007

"When Alzheimer's drugs arrive, they will do much good for the estimated 440,000 Americans that develop the disease each year. More than 5 million suffer from Alzheimer's in the U.S., according to the latest estimates from the Alzheimer's Association, and perhaps 24 million suffer worldwide."

The following are a few companies that develop drugs for Alzheimer's patients.

From Barron's 4/2/07

symbol name last price % change open
  • +
  • WYE
  • $0.00
  • 0.00%
  • $N/A

From Barron's 4/2/07 "Essner's company (ticker: WYE) has made a broad investment in Alzheimer's research, bringing 11 drugs into clinical human testing. Its lead compound is a genetically engineered antibody developed with the Irish firm Elan (ADR ticker: ELN) that actually clears away the toxic protein that clots Alzheimer's patients' brains. Other Wyeth compounds inhibit the formation of those Alzheimer's clumps."

People owning WYE also tend to own: ARXTCALPCAMH.OBFXIGSTLJTXKMP

TheStreet.com Rating: No Rating What is this?

  • +
  • NRMX
    N/a
  • $2.00
  • 0.00
  • $2.00

From Barron's 4/2/07 "The farthest along of the anti-amyloid experimental drugs are Myriad's Flurizan and Neurochem's Alzhemed, both of which are in the Phase 3 trials that come just prior to seeking FDA approval...The future of Canada's Neurochem basically rides on Alzhemed, an experimental drug that's like an anti-coagulant that binds to single copies of A-beta42 and reduces their tendency to clump together."

People owning NRMX also tend to own: AMKRANADBDYCBAKENZFRGIOC

TheStreet.com Rating: No Rating What is this?

  • +
  • ELN
    Elan Cp Plc Adr
  • $6.46
  • -2.71%
  • $6.56

From Barron's 4/2/07 "Essner's company (ticker: WYE) has made a broad investment in Alzheimer's research, bringing 11 drugs into clinical human testing. Its lead compound is a genetically engineered antibody developed with the Irish firm Elan (ADR ticker: ELN) that actually clears away the toxic protein that clots Alzheimer's patients' brains. Other Wyeth compounds inhibit the formation of those Alzheimer's clumps."

People owning ELN also tend to own: AMGNBWNGIASGITKG.OBBBYHOFFMOT

TheStreet.com Rating: No Rating What is this?

  • +
  • NVS
    Novartis Ag Ads
  • $53.13
  • -0.30%
  • $52.78

From Barron's 4/2/07 "Pfizer's Aricept and Novartis' Exelon prevent the breakdown of the neurotransmitter acetylcholine that's part of the mechanism of memory (as does Cognex, which Pfizer no longer actively markets)."

People owning NVS also tend to own: ANNAUYBACBHIERICFGE

TheStreet.com Rating: B What is this?

  • +
  • PFE
    Pfizer Inc
  • $18.36
  • +1.38%
  • $18.15

From Barron's 4/2/07 "Pfizer's Aricept and Novartis' Exelon prevent the breakdown of the neurotransmitter acetylcholine that's part of the mechanism of memory (as does Cognex, which Pfizer no longer actively markets)."

People owning PFE also tend to own: AAALLAPCBUDCOPCVXDOW

TheStreet.com Rating: C+ What is this?

  • +
  • LLY
    Lilly Eli Co
  • $36.59
  • +1.30%
  • $36.04

From Barron's 4/2/07 Produces a drug which "inhibits gamma secretase enzyme from making amyloid beta"

People owning LLY also tend to own: AIGALLBACCCATCBSCOP

TheStreet.com Rating: C What is this?

  • +
  • MYGN
    Myriad Genetics
  • $23.60
  • 0.00%
  • $N/A

From Barron's 4/2/07 "The farthest along of the anti-amyloid experimental drugs are Myriad's Flurizan and Neurochem's Alzhemed, both of which are in the Phase 3 trials that come just prior to seeking FDA approval."

People owning MYGN also tend to own: ABTACLAETALXNBAXBDXBIIB

TheStreet.com Rating: B- What is this?

  • +
  • JNJ
    Johnson And Johns
  • $62.31
  • +0.60%
  • $61.82

From Barron's 4/2/07 Produces a drug which "inhibits breakdown of memory neurotransmitters"

People owning JNJ also tend to own: AAAIGIBMINTCJPMKOMSFT

TheStreet.com Rating: B What is this?

previous next

Portfolio not tracked!

Comments not available

ADD YOUR COMMENTS:

Cramer's Take on Headline Stocks...

Not a Stockpickr member? Join the community today -- for free.Regardless of why a stock is in the news, it never hurts to hear what a professional investor has to say about...

11.20.09 | 11:48 AM
Jim Cramer's Portfolios of the Week

By Roberto Pedone Posted on Nov. 20, 2009 According to Jim Cramer, options expiration is driving the current market selloff. He pointed out that the only stocks that we...

11.20.09 | 08:09 AM
'Fast Money' Portfolios of the Week

By Roberto Pedone Posted on Nov. 19, 2009 According to CNBC’s “Fast Money” traders, the stock market is showing no signs of stopping its current bull run. Joe Ter...

11.19.09 | 11:13 AM
Squeezing the Shorts: Earnings G...

By Jonas Elmerraji Posted on Nov. 18, 2009 There are plenty of reasons for stocks to have the attention of short-sellers. Waning financials, a deteriorating business mo...

11.18.09 | 12:36 PM
more articles
General market Technical Analysi...
11.14.07 | 22:55 PM From author ZA
Nymph's Trading Daily Trading Diary
04.13.09 | 01:10 AM From author Trading Nymph
Simple headline speak "1,00...
11.23.09 | 00:02 AM From author graspthemarket
The Presidential/Political Thread
01.02.08 | 08:05 AM From author Dave Cox
more forums
Q. Am I diversified? My major hold...
11.22.09 | 21:36 PM Asked by fwtrader

A. a sector pair but not an industry pair
AAPL/AMT

today 's lists
Dogs of the Dow

Here are the 10 stocks in the Dow Jones Industrial Average stocks with the highest yields as of the market close on June 2, 2009. more

Cramer's Lightning Round

These are the stocks from Jim Cramer's Nov. 1 Lightning Round. We list the stocks on which he is BULLISH and BEARISH.... more

52-Week Lows

Here is a list of some of the biggest stocks that hit 52-week lows on Nov. 20, 2009. more